Examination of skin autofluorescence for the determination of glycation end-products in patients on chronic hemodialysis


Cite item

Full Text

Abstract

Aim. To assess the results of determination of glycation end-products (GEPs) by skin autofluorescence (AF) in patients on chronic hemodialysis (HD). Subjects and methods. A device made in Russia was used to estimate skin AF intensity in 40 apparently healthy individuals and in 76 patients treated with chronic HD. While analyzing the findings, comparisons were made in both groups; a relationship between skin AF intensity and clinical and laboratory parameters was also investigated in patients on HD. Results. The intensity of AF in the patients treated with chronic HD proved to be significantly higher than that in the control group. There was a direct correlation of the intensity of AF with age in both groups and that with the duration of dialysis treatment in patients on HD. In patients with coronary heart disease, the intensity of AF was significantly higher than in those without this condition. The intensity of AF directly correlated with the Charlson comorbidity index in the patients on HD. There were no correlations of skin AF intensity with main generally detected laboratory blood indicators, body mass index, and the nature of drug therapy in the patients on HD. Conclusion. Tissue GEP levels may serve as a cumulative index of metabolic stress in HD patients. The determination of GEP by measuring the intensity of skin AF may be used to assess prognosis in patients treated with chronic HD.

References

  1. Vanholder R, Glorieux G, De Smet R et al. New insights in uremic toxins. Kidney Int. 2003;84:S6-S10. doi: 10.1046/j.1523-1755.63.s84.43.x.
  2. Лукичев Б.Г., Подгаецкая О.Ю., Карунная А.В., Румянцев А.Ш. Индоксил сульфат при хронической болезни почек. Нефрология. 2014;18(1):25-32.
  3. Miyata T, Wada Y, Cai Z et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int. 1997;51(4):1170-1181. doi: 10.1038/ki.1997.160.
  4. Meerwaldt R, Hartog JW, Graaf R et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16(12):3687-3693. doi: 10.1681/ASN.2005020144.
  5. Uribarri J, He JC. The low AGE diet: a neglected aspect of clinical nephrology practice? Nephron. 2015;130(1):48-53. doi: 10.1159/000381315.
  6. Stirban A, Tshope D. Vascular effects of dietary advanced glycation end products. Int J Endocrinol. 2015. doi: 10.1155/2015/836498.
  7. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol. 2006;1(6):1293-1299. doi: 10.2215/CJN.01270406.
  8. Daroux M, Prevost G, Maillard-Lefebvre H et al. Advanced glycation end -products: implications for diabetic and non-diabetic nephropathies. Diabetes Metab. 2010;36(1):1-10. doi: 10.1016/j.diabet.2009.06.005.
  9. Chuang PY, Yu Q, Fang W et al. Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor. Kidney Int. 2007;72(8):965-976. doi: 10.1038/sj.ki.5002456.
  10. Yamamoto Y, Kato I, Doi T et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108(2):261-268. doi: 10.1172/JCI11771.
  11. Peppa M, Uribarri J, Cai W et al. Glycoxidation and inflammation in renal failure patients. Am J Kidney Dis. 2004;43(4):690-695. doi: 10.1053/j.ajkd.2003.11.022.
  12. Friedlander MA, Wu YC, Schulac JA et al. Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis. 1995;25(3): 445-451. doi: 10.1016/0272-6386(95)90107-8.
  13. Fagugli RM, De Smet R, Buoncristiani U et al. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002;40(2):339-347. doi:10/1053/ajkd.2002.34518.
  14. Gerdemann A, Wagner Z, Solf A et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant. 2002;17(6):1045-1049. doi: 10.1093/ndt/17.6.1045.
  15. Lin CL, Huang CC, Yu CC et al. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis. 2003;42(3):524-531. doi: 10.1016/S0272-6386(03)00747-9.
  16. Mac-Way F, Couture V, Utescu MS et al. Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis. Int Urol Nephrol. 2014;46(4):817-824. doi: 10.1007/s11255-013-0597-6.
  17. Slowik-Zylka D, Safranow K, Dziedziejko V et al. Association of plasma pentosidine concentrations with renal function in kidney graft recipients. Clin Transplant. 2010;24(6):839-847. doi: 10.1111/j.1399-0012.2009.01176.x.
  18. Janda K, Krzanowski M, Gajda M et al. Vascular effects of advanced glycation end products: content of immunohistochemically detected AGEs in radial artery samples as a predictor for arterial calcification and cardiovascular risk in asymptomatic patients with chronic kidney disease. Dis Markers. 2015. doi: 10.1155/2015/153978.
  19. Schwedler SB, Metzger T, Schinzel R, Wanner C. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002;62(1):301-310. doi: 10.1046/j.1523-1755.2002.00423.x.
  20. Busch M, Franke S, Muller A et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int. 2004;66(1): 338-347. doi: 10.1111/j.1523-1755.2004.00736.x.
  21. Ok ES, Asci G, Toz H et al. Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patients. Clin Nephrol. 2014;82(3):173-180. doi: 10.5414/CN108251.
  22. Meerwaldt R, Graaf R, Oomen PH et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47(7):1324-1330. doi: 10.1007/s001125-004-1451-2.
  23. Папаян Г.В., Березин В.Б., Петрищев Н.Н. и др. Спектрометр для флуоресцентно-отражательных биомедицинских исследований. Оптический журнал. 2013;1:56-67.
  24. Amann K, Ritz E. Cardiovascular abnormalities in ageing and in uraemia — only analogy or shared pathomechanisms? Nephrol Dial Transplant. 1998;13(Suppl 7):6-11. doi: 10.1093/ndt/13.suppl_7.6.
  25. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290(14):697-701. doi: 10.1056/NEJM197403282901301.
  26. Kooman JP, Broers NJ, Usvyat L et al. Out of control: accelerated aging in uremia. Nephrol Dial Transplant. 2013; 28(1): 48-54. doi: 10.1093/ndt/gfs451.
  27. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism. 2005;54(3):345-350. doi: 10.1016/j.metabol.2004.09.014.
  28. Noordzij MJ, Lefrandt JD, Loeffen EA et al. Skin autofluorescence is increased ih patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging. 2012;28(2):431-438. doi: 10.1007/s10554-011-9805-6.
  29. Aronson D. Pharmacological prevention of cardiovascular aging — targeting the Maillard reaction. Br J Pharm. 2004;142:1055-1058. doi: 10.1038/sj.bjp.0705832.
  30. Utescu MS, Couture V, Mac-Way F et al. Determinants of progression of aortic stiffness in hemodialysis patients. Hypertension. 2013;62(1):154-160. doi: 10.1161/HYPERTENSIONAHA.113.01200.
  31. Sims TJ, Rasmussen LM, Oxlund H, Bailey AJ. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia. 1996;39(8):946-951. doi: 10.1007/BF00403914.
  32. Tanikawa T, Okada Y, Tanikawa R, Tanaka Y. Advanced glycation end products induce calcification of vascular smooth muscle cells through RAGE/p38 MAPK. J Vasc Res. 2009;46(6):572-580. doi: 10.1159/000226225.
  33. Ren X, Shao H, Wei Q et al. Advanced glycation end-products enhance calcification in vascular smooth muscle cells. J Int Med Res. 2009;37(3):847-854. doi: 10.1177/147323000903700329.
  34. Sanguinetti R, Puddu A, Mach F et al. Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm. 2014. doi: 10.1155/2014/975872.
  35. Monnier VM, Mustata GT, Biemel KL et al. Cross-linking of the extracellular matrix by the Maillard reaction in aging and diabetes: an update on «a puzzle nearing resolution». Ann NY Acad Sci. 2005;1043:533-544. doi: 10.1196/annals.1333.061.
  36. Monden M, Koyama H, Otsuka Y et al. Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes. 2013;62(2):478-489. doi: 10.2337/db11-1116.
  37. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis. 2008;196(1):9-21. doi: 10.1016/j.atherosclerosis.2007.07.025.
  38. Sung JY, Chung W, Kim AJ et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013;230(1):59-66. doi: 10.1620/tjem.230.59.
  39. Mahajan N, Malik N, Bahl A, Dhawan V. Receptor for advanced glycation end products (RAGE) ant its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease. Atherosclerosis. 2009;207(2):597-602. doi: 10.1016/j.atherosclerosis.2009.06.003.
  40. Park S, Yoon SJ, Tae HJ, Shim CY. RAGE and cardiovascular disease. Front Biosci. 2011;16:486-497. doi: 10.2741/3700.
  41. Nakashima A, Carrero JJ, Qureshi AR et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(12):2213-2219. doi: 10.2215/CJN.03360410.
  42. Basta G, Sironi AM, Lazzerini G et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006;91(11):4628-4634. doi: 10.1210/jc.2005-2559.
  43. Basta G, Leonardis D, Mallamaci F et al. Circulating soluble receptor of advanced glycation end products inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77(3):225-231. doi: 10.1038/ki.2009.419.
  44. Kislinger T, Fu C, Huber B et al. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274(44):31740-31749. doi: 10.1074/jbc.274.44.31740.
  45. Ramasamy R, Yan SF, Schmidt AM. Advanced glycation end products: from precursors to RAGE: round and round we go. Amino Acids. 2012;42(4):1151-1161. doi: 10.1007/s00726-010-0773-2.
  46. Bierhaus A, Humpert PM, Morcos M et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83(11):876-886. doi: 10.1007/s00109-005-0688-7.
  47. Vlassara H, Cai W, Goodman S et al. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the anti-inflammatory AGE-receptor-1. J Mol Med. 2005;83(11):876-886. doi: 10.1210/jc.2009-0089.
  48. Uribarri J, Peppa M, Cai W et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14(3):728-731. doi: 10.1097/01.ASN.0000051593.41395.B9.
  49. White WE, Yaqoob MM, Harwood SM. Aging and uremia: is there cellular and molecular crossover? World J Nephrol. 2015;4(1):19-30. doi: 10.5527/wjn.v4.i1.19.
  50. Ziegler DV, Wiley CD, Velarde MC. Mitochondrial effectors of cellular senescence: beyond the free radical theory of aging. Aging Cell. 2015;14(1):1-7. doi: 10.1111/acel.12287.
  51. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404(6779):787-790. doi: 10.1038/35008121.
  52. Nelson MB, Swensen AC, Winden DR et al. Cardiomyocyte mitochondrial respiration is reduced by receptor for advanced glycation end-products (RAGE) signaling in a ceramide-dependent manner. Am J Physiol Heart Circ Physiol. 2015;309(1):H63-69. doi: 10.1152/ajpheart.00043.2015.
  53. Franceschi C, Bonafe M. Centenarians as a model for healthy aging. Biochem Soc Trans. 2003;31(2):457-461. doi: 10.1042/bst0310457.
  54. Monnier VM, Bautista O, Kenny D et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48(4):870-880. doi: 10.2337/diabetes.48.4.870.
  55. van Manen JG, Korevaar JC, Dekker FW et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis. 2002;40(1):82-89. doi: 10.1053/ajkd.2002.33916.
  56. Wagner Z, Molnar M, Molnar GA et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis. 2006;47(2):294-300. doi: 10.1053/j.ajkd.2005.10.010.
  57. Gerrits EG, Lutgers HL, Smeets GH et al. Skin autofluorescence: a pronounced marker of mortality in hemodialysis patients. Nephron Extra. 2012;2(1):184-191. doi: 10.1159/000339282.
  58. Папаян Г.В., Есаян А.М., Каюков И.Г. и др. Измерение конечных продуктов гликирования в коже при хронической болезни почек методом автофлуоресцентной спектроскопии. Клиническая нефрология. 2014;6:17-22.
  59. Forbes JM, Cooper ME, Thallas V et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51(11):3274-3282.
  60. Vlassara H, Uribarri J, Cai W et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934-942. doi: 10.2215/CJN.12891211.
  61. Muller-Krebs S, Nissle K, Tsobaneli J et al. Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid. Front Med (Lausanne). 2015;2:10. doi: 10.3389/fmed.2015.00010.
  62. Yubero-Serrano EM, Woodward M, Poretsky L et al. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol. 2015;10(5):759-766. doi: 10.2215/CJN.07750814.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies